Onerji receives sales authorization from the European Commission

Onerji®—a Parkinson's disease therapy developed by NeuroDerm, a subsidiary of Tanabe Pharma—obtained formal marketing authorization in the European Union (EU) on 27 April 2026. The approval is significant because it offers a new option for patients with progressive Parkinson's disease whose symptoms are insufficiently controlled by oral medications. Onerji is a levodopa/carbidopa combination delivered via a small pump that provides continuous subcutaneous infusion over 24 hours, representing a drug‑device combination. By eliminating the plasma concentration spikes and troughs associated with oral dosing, it is expected to markedly improve patients’ quality of life.

Phase III BouNDless trial demonstrates superior efficacy

The authorization is based on the global Phase III BouNDless study, which compared Onerji with standard oral levodopa/carbidopa therapy in patients with progressive Parkinson's disease. The trial showed that the Onerji arm achieved a statistically significant increase of 1.72 hours per day in “Good ON” time (time without dyskinesia) versus the oral arm (p < 0.0001). It also significantly reduced “OFF” time, the periods when medication effect wanes. Continuous 24‑hour subcutaneous infusion maintained stable levodopa plasma levels, normalizing dopaminergic stimulation in the brain.

Differentiated formulation positions Onerji against competitor AbbVie

The European Parkinson’s disease market includes several generics as well as AbbVie’s intestinal gel formulation, Duopa®. Duopa requires an invasive surgical procedure to place a tube into the gut, whereas Onerji utilizes a non‑invasive subcutaneous injector, offering a clear advantage in patient convenience. Although AbbVie has secured approval for a similar subcutaneous product, Vyalev®, Onerji’s proprietary delivery system supports patient‑friendly management. The ability to self‑administer at home without surgery is a key asset that could dramatically improve treatment accessibility.

U.S. market delay and European reimbursement negotiations present challenges

Successful entry into the European market will require rapid price negotiations and reimbursement listings with national health authorities. Demonstrating Onerji’s cost‑effectiveness against low‑priced oral generics is essential for swift market uptake. Meanwhile, Onerji has received two Complete Response Letters (CRLs) from the U.S. FDA—in June 2024 and October 2025—citing manufacturing site and non‑clinical data deficiencies, delaying U.S. launch. Consequently, an early European launch combined with favorable pricing agreements is critical for Tanabe Pharma to offset regulatory uncertainty in the United States.

R&D investment begins to pay off, accelerating capture of a large market

The global Parkinson’s disease therapy market is estimated at $6.2–$7.7 billion in 2026 and is projected to exceed $14 billion by 2035 driven by an aging population. The share of sustained‑release delivery systems for advanced patients is expanding rapidly, increasing Onerji’s potential value. Tanabe Pharma’s 2017 acquisition of NeuroDerm for $1.1 billion secured this pipeline, and the recent approval marks the fruition of that long‑term investment. If the product also gains U.S. approval, Onerji could become a global blockbuster and a core cash‑cow for the company.